The biotechnology company focuses on restoring gluten tolerance in celiac disease through immunology discoveries. Its Nexvax2 therapeutic vaccine treats, prevents, and diagnoses the disease. ImmusanT also offers a functional T-cell test for immune tolerance maintenance with peptide-based therapy. Its precision medicine approach helps clinicians diagnose and manage autoimmune diseases, including celiac disease and type 1 diabetes. Incorporated in 2010, ImmusanT is headquartered in Cambridge, Massachusetts.